Menu
ncarol.com
  • Home
  • Books
  • Book Release
  • Health
  • Business
  • Real Estate
  • Financial
  • Arts
  • Non-profit
ncarol.com

HCPs Anticipate Disruption of Oral T2D Landscape by Division
ncarol.com/10211391

Trending...
  • Director Sean McNamara Reunites with Award-Winning Cinematographer Shawn Seifert for Upcoming Feature Home
  • Florida Law Advisers, P.A. Named Best Divorce Firm of 2026 by Expert Law Attorneys
  • Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
RESEARCH TRIANGLE PARK, N.C. - ncarol.com -- A variety of factors are considered when healthcare providers (HCPs) speak upon which type 2 diabetes treatments in the clinical pipeline may be more disruptive and why. According to newly published data by market research from Vivisum Partners, LLC., new arrivals are likely to take some pieces of the current share of oral treatments on market, but it may be enough to cause some dents in multiple treatments due to viable alternatives.

The current market holds a lot of excitement for the oral type 2 diabetes pipeline for drugs that are just as comparable in tolerability, but may differ on other clinical attributes, such as dosing. The most potential risk for a more established treatment will be pipeline products gaining more access.

For example, according to Oral T2D Clinical Pipeline, many HCPs expect oral Insulin's efficacy to be slightly or much better than current oral T2D treatments. In dosing, oral Insulin is believed to be slightly better according to a significant percentage of endocrinologists. Familiarity with HCPs could represent much of the difference in access for patients.

More on ncarol.com
  • Rev-O-Box™ Launches Reversible Shipping Box That Instantly Becomes a Premium Gift Box
  • Las Vegas Estate Firm Ghandi Deeter Blackham Offers Insight on Tony Hsieh's Contested $500 Million Will
  • Ms. Marie's Coffee Blend Launches Local Delivery Service Beginning in Lexington, North Carolina
  • CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe

Despite significant excitement for physicians who are familiar with oral insulin there is significant excitement. There is an overall low level of familiarity with other oral T2D pipeline medications. Only 21% of HCPs are familiar with oral insulin, which is the highest percentage of familiarity among any clinical pipeline treatment.

Vivisum Partners surveyed Endocrinologists and HCPs about each oral type 2 diabetes pipeline therapy. The survey results specify their degree of excitement, "HCPs are evenly split between being excited (48%) vs. ambivalent (48%) towards Sotagliflozin", -said Vivisum's Oral Type 2 Diabetes strategist Patrick Brunell. He adds, this suggests that HCPs are interested in Sotagliflozin, but remain skeptical on how well it will perform in the market." Most Endocrinologists (80%) believe that Sotagliflozin will have about the same level of access as current diabetes medications.

Many of the metrics used in the report show that established treatments may have to get used to sharing larger portions of the Oral T2D marketplace. Relying on brand recognition may or may not be enough. Oral T2D Clinical Pipeline Analysis, https://vivisumpartners.com/reports/new-diabetes-medications-clinical-pipeline-analysis/, published in January 2023 by Vivisum Partners, examines each oral type 2 diabetes drug's strengths and weaknesses across six key clinical attributes:
  • Access
  • Dosing
  • Efficacy
  • Safety
  • Support
  • Tolerability

ABOUT VIVISUM PARTNERS, LLC

More on ncarol.com
  • Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
  • Achugogo: Tale of the Spring Chaser Wins Inaugural TCCF Prize at Mifa Pitches, the Industry Market of the Annecy International Animation Film Festival
  • Everything Policy Launches Madison, an AI Tool That Makes Legislation Readable for Students and Citizens
  • TOLI North America Implements Modest Price Increase, Absorbing Majority of Costs
  • Is the Market Missing One of the Most Undervalued Cybersecurity Companies on the Stock Market? Cycurion, Inc. (N A S D A Q: CYCU):

Vivisum Partners, LLC is a market research agency providing strategic consulting around marketing and brand building. Vivisum provides facilitated discovery using market research methodologies and critical thinking processes. The actionable market research insights that Vivisum provides enable clients to shape their commercial strategies.

Contact
Candice Smith
***@vivisumpartners.com


Source: Vivisum Partners, LLC

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Qscription Technologies Appoints Radiology Industry Veteran Elliot Silverman to Advisory Board
  • Search Is Broken. Curated Discovery Is the Future
  • While iHeartMedia Cuts Jobs, Radio Stations Nationwide Are Hiring
  • 20 Ways to Save Money Running a Van
  • How Fortress Law Group Turned a DUI Arrest in Ohio Into a Full Acquittal at Trial
  • Breaking the Silence: Tour Sparks National Conversation on Men's Mental Health and Domestic Abuse
  • Mr. Hospital Bed Helps Home Care Buyers Find the Right Hospital Bed
  • The KettleBelle Achieves Explosive 400% Member Growth in Four Months, Launches 5-Day Kickstart
  • Soma and Sage Bringing Functional Mobility and Nervous System Regulation to Burlington NC
  • Able Rooter Expands Services to Offer Premium Water Heater Installation Across St. Louis
  • Director Sean McNamara Reunites with Award-Winning Cinematographer Shawn Seifert for Upcoming Feature Home
  • J. Kenton Pierce Wins Prometheus Award for Best Novel
  • Class is in session: Black Beauty Block Party returns to Los Angeles for fourth annual festival
  • Heavy Duty Journal Surpasses 1000 Technical Articles for Diesel Technicians and Fleet Managers
  • Kolbus Introduces the Next Step in Casemaking Efficiency
  • Florida Law Advisers, P.A. Named Best Divorce Firm of 2026 by Expert Law Attorneys
  • Sounds of LA County: 27 Parks.108 Concerts. One County
  • Only One Flight Stands Between Los Angeles Youth Leaders and a Life-Saving Mission in South Africa
  • BumblebeeSmart Announces Partnership with Extreme Kids World to Expand Access to Sensory Wall Panels and Educational Busy Boards
  • Stigma Across Borders: Concerns Grow Over Discrimination Against Shincheonji Members Abroad
_catLbl0 _catLbl1

Popular on ncarol.com

  • RAS AP Consulting Expands AP Governance & Automation Practice and Named Finalist for Heidelberg Materials SAP Vendor & Customer Data Project - 125
  • Psychiatric Hospitals Fail to Warn Electroshock Patients of FDA-Cited Risks in Estimated $7 Billion Industry - 118
  • Sexually Abused in a Psychiatric Hospital or Psychiatrist's or Psychologist's Office? CCHR Urges Survivors to Reach Out to It - 114
  • George Martinez Launches Community Re-distribution Initiative With Donation to the Gamma Alpha Alpha Chapter of Omega Psi Phi Fraternity, Inc - 103
  • Healthcare Leaders Publish New Integrated Behavioral Healthcare Guide, Led by Doctors of Behavioral Health
  • Nayarit Strengthens Its Position as a Global Surf Destination; Sayulita to Become Mexico's First Official Surf City
  • DuoKey Launches Quantum Risk Score to Help Enterprises Prioritise Post-Quantum Cryptography Migration
  • This Weekend Causeway Cove Country BBQ & Music Festival Returns for Fourth Year, Celebrating America's 250th Anniversary on the Water
  • Wagga Trucks set to expand to the Canberra Region as authorised dealer for Volvo, UD & Mack along with Freighter Group Trailers
  • UK Financial Ltd. Opens Test-Phase Maya 3 Liquidity Pool on Uniswap with DEX Screener Visibility for Market-Smoothing Ahead of CATEX Exchange Launch

Similar on ncarol.com

  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute